Literature DB >> 18350378

Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.

Tehila Mayer-Sonnenfeld1, Dana Avrahami, Yael Friedman-Levi, Ruth Gabizon.   

Abstract

Prion diseases are a group of fatal neurodegenerative diseases affecting humans and animals. The only identified component of the infectious prion is PrP(Sc), an aberrantly folded isoform of PrP(C). Glycosaminoglycans, which constitute the main receptor for prions on cells, play a complex role in the pathogenesis of prion diseases. For example, while agents inducing aberrant lysosomal accumulation of GAGs such as Tilorone and Quinacrine significantly reduced PrP(Sc) content in scrapie-infected cells, administration of Quinacrine to prion-infected subjects did not improve their clinical status. In this study, we investigated the association of PrP(Sc )with cells cultured with Tilorone. We found that while the initial incorporation of PrP(Sc) was similar in the treated and untreated cells, clearance of PrP(Sc) from the Tilorone-treated cells was significantly impaired. Interestingly, prolonged administration of Tilorone to mice prior to prion infection resulted in a significant delay in disease onset, concomitantly with in vivo accumulation of lysosomal GAGs. We hypothesize that GAGs may complex with newly incorporated PrP(Sc) in lysosomes and further stabilize the prion protein conformation. Over-stabilized PrP(Sc) molecules have been shown to comprise reduced converting activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18350378     DOI: 10.1007/s10571-008-9274-1

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  52 in total

Review 1.  Prions and the lymphoreticular system.

Authors:  C Weissmann; A J Raeber; F Montrasio; I Hegyi; R Frigg; M A Klein; A Aguzzi
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-02-28       Impact factor: 6.237

2.  Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo.

Authors:  David A Kocisko; Byron Caughey
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 3.  Drug-induced lysosomal storage of sulphated glycosaminoglycans.

Authors:  J Fischer; H Lüllmann; R Lüllmann-Rauch
Journal:  Gen Pharmacol       Date:  1996-12

Review 4.  The biochemical basis for mucopolysaccharidoses and mucolipidoses.

Authors:  E F Neufeld
Journal:  Prog Med Genet       Date:  1974

5.  The anti-prion activity of Congo red. Putative mechanism.

Authors:  S Caspi; M Halimi; A Yanai; S B Sasson; A Taraboulos; R Gabizon
Journal:  J Biol Chem       Date:  1998-02-06       Impact factor: 5.157

Review 6.  Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases.

Authors:  Javier Díaz-Nido; Francisco Wandosell; Jesús Avila
Journal:  Peptides       Date:  2002-07       Impact factor: 3.750

7.  Up-regulation of cathepsin B and cathepsin L activities in scrapie-infected mouse Neuro2a cells.

Authors:  Yonghua Zhang; Eberhard Spiess; Martin H Groschup; Alexander Bürkle
Journal:  J Gen Virol       Date:  2003-08       Impact factor: 3.891

8.  Combined alcian blue and silver staining of subnanogram quantities of proteoglycans and glycosaminoglycans in sodium dodecyl sulfate-polyacrylamide gels.

Authors:  H J Møller; D Heinegård; J H Poulsen
Journal:  Anal Biochem       Date:  1993-02-15       Impact factor: 3.365

9.  Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies.

Authors:  Ikuko Murakami-Kubo; Katsumi Doh-Ura; Kensuke Ishikawa; Satoshi Kawatake; Kensuke Sasaki; Jun-Ichi Kira; Shigeru Ohta; Toru Iwaki
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Copper binding to PrPC may inhibit prion disease propagation.

Authors:  Nuha Hijazi; Yuval Shaked; Hana Rosenmann; Tamir Ben-Hur; Ruth Gabizon
Journal:  Brain Res       Date:  2003-12-12       Impact factor: 3.252

View more
  4 in total

1.  Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection.

Authors:  Sean Ekins; Mary A Lingerfelt; Jason E Comer; Alexander N Freiberg; Jon C Mirsalis; Kathleen O'Loughlin; Anush Harutyunyan; Claire McFarlane; Carol E Green; Peter B Madrid
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

Review 2.  Cell biology of prion strains in vivo and in vitro.

Authors:  Daniel Shoup; Suzette A Priola
Journal:  Cell Tissue Res       Date:  2022-02-02       Impact factor: 5.249

3.  A systems approach to prion disease.

Authors:  Daehee Hwang; Inyoul Y Lee; Hyuntae Yoo; Nils Gehlenborg; Ji-Hoon Cho; Brianne Petritis; David Baxter; Rose Pitstick; Rebecca Young; Doug Spicer; Nathan D Price; John G Hohmann; Stephen J Dearmond; George A Carlson; Leroy E Hood
Journal:  Mol Syst Biol       Date:  2009-03-24       Impact factor: 11.429

4.  Machine learning models identify molecules active against the Ebola virus in vitro.

Authors:  Sean Ekins; Joel S Freundlich; Alex M Clark; Manu Anantpadma; Robert A Davey; Peter Madrid
Journal:  F1000Res       Date:  2015-10-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.